China Food For Special Medical Purpose Market Size, Share & Trends Analysis Report By Route Of Administration (Oral, Enteral), By Product (Pills, Powder, Liquid), By Application, By Modules, By Sales Channel, And Segment Forecasts, 2025 - 2030

Market Size & Trends

The China food for special medical purpose market size was estimated at USD 2.27 billion in 2024 and is expected to grow at a CAGR of 6.58% from 2025 to 2030. The growth is attributed to the aging population, increasing prevalence of chronic diseases, rising malnutrition rates, and supportive regulatory frameworks. These factors contribute to the expanding demand for specialized nutritional products tailored to meet the unique needs of various patient groups. For instance, in July 2022, Nestlé introduced China's first food for special medical purpose (FSMP) specifically designed for patients with tumor-related conditions, following a five-year approval process by Chinese regulatory authorities.

The rising prevalence of chronic diseases such as hypertension, diabetes, and cancer is another significant driver. These conditions often lead to complications such as malnutrition and weight loss, increasing the need for specialized nutritional interventions. FSMPs formulated to support individuals with chronic illnesses help manage symptoms, improve quality of life, and reduce healthcare costs associated with malnutrition and related complications.

The Chinese government maintained the regulatory framework for Foods for Special Medical Purposes (FSMPs), with growing advocacy for future reimbursement coverage. The regulatory oversight for FSMPs is managed by the National Medical Products Administration (NMPA), formerly the China Food and Drug Administration (CFDA), facilitating product approvals and supporting market growth. As of September 2024, China had 206 registered FSMPs; of these, 174 are domestically produced, while 32 are imported, with domestically produced products significantly outnumbering imported ones. Among the approved products, 153 are powdered, and the remaining 53 are liquid.

A total of 66 FSMP products were approved for registration in 2024, originating from 17 different provinces and regions across China. Jiangsu, Shandong, and Heilongjiang emerged as the top three contributors, with 21, 10, and 6 approvals, respectively. These figures represent 32%, 15%, and 9% of the total registrations for the year.

The COVID-19 pandemic impacted China’s FSMP market by accelerating the demand for clinical nutrition products amid increased health awareness and medical needs. During the pandemic, the focus on patient care for vulnerable populations, such as those with chronic illnesses or compromised immunity, increased the reliance on specialized nutritional support to aid recovery and improve health outcomes. Several sectors faced economic downturns and cautious consumer spending, and healthcare and nutrition-related industries, including FSMP, saw growing attention due to their critical role in disease management and prevention. In addition, the pandemic expedited digital transformation and modernization in China’s healthcare system, facilitating better distribution, remote consultations, and awareness of FSMP products. The challenges, such as disrupted supply chains and regulatory adjustments, influenced market dynamics. Overall, COVID-19 catalyzed increased clinical nutrition adoption in China, setting the stage for sustained growth in the FSMP market as part of the country’s broader healthcare recovery and modernization efforts.

China Food For Special Medical Purpose Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the China food for special medical purpose (FSMP) market report based on route of administration, product, application, modules, and sales channel.

• Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
• Oral
• Enteral
• Product Outlook (Revenue, USD Million, 2018 - 2030)
• Pills
• Powder
• Liquid
• Others (semisolid, semiliquid)
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Chronic Kidney Disease
• Minimal Hepatic Encephalopathy
• Chemotherapy Induced Diarrhea
• Pathogen Related Infections
• Diabetic Neuropathy
• ADHD
• Depression
• Alzheimer's Disease
• Nutritional Deficiency
• Orphan Diseases
• Tyrosinemia
• Eosinophilic Esophagitis
• Food Protein Module-induced enterocolitis syndrome (Food Protein Module-induced enterocolitis syndrome (FPIES))
• Phenylketonuria (PKU)
• Maple syrup urine disease (Maple syrup urine disease (MSUD))
• Homocystinuria
• Others (Urea Cycle Disorder (UCD), Glycogen Storage Disease (GSD), etc.)
• Wound Healing
• Chronic Diarrhea
• Constipation Relief
• Protein Booster
• Dysphagia
• Pain Management
• Parkinson's Disease
• Epilepsy
• Other Cancer related treatments
• Severe Protein Allergy
• Cancer
• Cachexia
• Other (debilitating conditions, COPD, etc.)
• Modules Outlook (Revenue, USD Million, 2018 - 2030)
• Amino Acid Module
• Protein Module
• Vitamin & Mineral Modules
• Fatty Acid based Modules
• Carbohydrate Modules
• Fiber Modules
• Ketogenic Modules
• Peptide based Modules
• Hypoallergic Modules
• Others (Electrolyte Module, etc.)
• Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)
• DTC Sales Channel
• Online Sales
• Retail Sales
• Institutional Sales
• Hospitals
• Others (Long-term Care Facilities, etc.)

Please note The report will be delivered in 2-3 business days upon order notification. Show more